Anti-Mouse MHC Class I (H-2Kk, H-2Dk) (Clone 15-3-1S) – Purified in vivo GOLD™ Functional Grade

Clone 15-3-1S is a monoclonal antibody specific for mouse MHC Class I molecules H-2Kk and H-2Dk, and its principal in vivo application in mice is blocking MHC Class I function to prevent immune responses such as allograft rejection.

Common in vivo applications of clone 15-3-1S in mice include:

• Prevention of islet allograft rejection: It has been used to block MHC Class I mediated recognition during islet transplantation, thereby preventing rejection in diabetic mouse models.
• Blockade of antigen presentation: By binding to H-2Kk and H-2Dk, 15-3-1S prevents CD8+ T cells from recognizing peptide-MHC complexes, which is useful for studying the role of MHC Class I in immune responses.
• Immunosuppression in transplantation studies: Used to investigate how the absence of MHC Class I interaction impacts allogeneic immune responses, tolerance, and graft survival.
• Experimental models of immune modulation: Facilitates research on adaptive immunity and transplantation tolerance by selectively inhibiting class I mediated pathways.

The antibody is purified for low endotoxin levels to minimize off-target effects and allow safe in vivo administration in pre-clinical immunological and transplantation research. No evidence indicates its use for depletion; rather, its primary mechanism is competitive blockade of the targeted MHC molecules.

Commonly used antibodies or proteins together with 15-3-1S (which is a monoclonal antibody against mouse MHC Class I molecules, specifically H-2Kk and H-2Dk), include other antibodies against different mouse MHC molecules and proteins relevant to immunology and oncology research.

Essential context:

• 15-3-1S is employed specifically to detect mouse MHC Class I antigens H-2Kk and H-2Dk in immunological assays.

• In experiments using 15-3-1S, researchers frequently use companion antibodies that target other MHC molecules, such as:

  • Anti-H-2Kb
  • Anti-H-2Db
  • Anti-H-2Dd
  • Anti-H-2Kq
  • Anti-beta2-microglobulin
    These allow for broader profiling of MHC Class I expression or for comparison of different haplotypes in mouse models.

• When 15-3-1S is used in multi-parameter flow cytometry or immunohistochemistry, these antibodies are typically conjugated to different fluorophores for simultaneous detection.

• In studies of immune response or transplantation, additional antibodies that target other immune cell markers (such as anti-CD4, anti-CD8, or anti-CD45) are often used alongside 15-3-1S to characterize cell populations.

Additional relevant information:

• Although CA15-3 (MUC1) is mentioned in breast cancer literature and uses a different numbering system and context (referring to a human cancer biomarker), it is unrelated to the mouse MHC Class I antibody 15-3-1S. If you meant CA15-3, other widely used antibodies include anti-MUC1, anti-CA125, various lectins, and HRP-conjugated anti-IgG.

• If your focus is mouse immunology or transplantation, consider including antibodies relevant to your mouse strain or immune cell type, as standard panels are typically used.

If further clarification or a specific context (such as a disease model or technique—e.g., flow cytometry, immunohistochemistry) is needed, please specify to refine the list.

The key scientific findings regarding clone 15-3-1S are not directly encountered in the search results. It is likely you are referring to HL-60 clone 15 (sometimes cited as HC15) or related leukocyte cell line clones frequently used in immunological research. Below, I synthesize the main findings associated with HL-60 clone 15 from the available scientific literature:

• HL-60 clone 15 (HC15) is valuable as a model for studying leukocyte migration and differentiation, particularly for generating eosinophil-like cells through sodium butyrate treatment—sometimes in combination with IL-5.
• Characterization efforts include proteomics, morphologic assessment, RT-qPCR, immunofluorescent staining, and flow cytometry, comparing HC15 cells to primary eosinophils, neutrophils, and peripheral blood mononuclear cells.
• Differentiation and similarity: Upon differentiation, HC15 cells display protein expression patterns shifting toward primary eosinophils, especially in granule and adhesion proteins. PCA clustering shows that HC15 cells cluster closer to eosinophils than neutrophils along principal component 1, though principal component 2 reveals more similarity with neutrophils. Differentiation increases eosinophil-like characteristics but does not fully replicate primary cell phenotypes.
• Functional studies: Past research primarily assessed chemotaxis and granule protein expression. More comprehensive functional assays such as migration, aggregate formation, adherence to endothelial cells, and activation via ELISA/flow cytometry have also been performed to further validate its modeling capacities.
• Limitations: The cell line does not consistently reproduce all functional aspects of primary eosinophils. Methods and markers for evaluating differentiation remain heterogeneous and sometimes insufficient for full validation as a substitute for primary cells.
• Source and background: HL-60 clone 15 is a subline derived from the HL-60 cell lineage, established from a patient with acute promyelocytic leukemia, and is a common model for hematopoietic research.

If you intended clone 15-3-1S from a different context (e.g., microbial, plasmid, or non-HL-60 cell line), please specify details for precise literature coverage—none of the provided search results referenced “15-3-1S” as a distinct entity. The above synthesis addresses findings on the most closely related and frequently cited “clone 15” in immunology.

Based on the available search results, I was unable to find specific information about dosing regimens for clone 15-3-1S across different mouse models. The search results provided detailed dosing information for various other antibody clones used in mouse research, including checkpoint blockade antibodies (RMP1-14, 10F.9G2, 29F.1A12, 9H10, 9D9) and immune cell depleting antibodies (GK1.5, 2.43, RB6-8C5), but clone 15-3-1S was not mentioned in any of the sources.

The search results do demonstrate general principles for antibody dosing in mouse models that typically apply across different clones. Standard considerations that influence dosing regimens in mouse studies include:

Key Variables Affecting Dosing

The application and experimental objective significantly impact dose selection. For checkpoint blockade antibodies, standard doses typically range from 100-500 μg per mouse, administered intraperitoneally every 3-4 days. For immune cell depleting antibodies, doses generally range from 200-250 μg per mouse, given 2-3 times per week.

Target Engagement and Model-Specific Factors

Dosing regimens are determined by target engagement, mouse strain characteristics, and the specific experimental model being used. The route of administration, frequency of dosing, and total duration of treatment all require optimization based on the particular research question and model system.

To obtain accurate dosing information for clone 15-3-1S specifically, I would recommend consulting the antibody manufacturer's technical specifications, reviewing published literature that used this particular clone, or contacting the supplier directly for model-specific recommendations.